Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice

被引:60
作者
Berbee, Jimmy F. P. [1 ,2 ]
Wong, Man C. [1 ,3 ]
Wang, Yanan [1 ]
van der Hoorn, Jose W. A. [4 ]
Khedoe, Padmini P. S. J. [1 ,3 ]
van Klinken, Jan B. [5 ]
Mol, Isabel M. [1 ]
Hiemstra, Pieter S. [3 ]
Tsikas, Dimitrios [6 ]
Romijn, Johannes A. [1 ]
Havekes, Louis M. [1 ,4 ,7 ]
Princen, Hans M. G. [4 ]
Rensen, Patrick C. N. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Gen Internal Med Endocrinol & Metab Dis, NL-2300 RC Leiden, Netherlands
[2] Sanquin Res Amsterdam, Dept Expt Immunohematol, Amsterdam, Netherlands
[3] Leiden Univ, Med Ctr, Dept Pulmonol, NL-2300 RC Leiden, Netherlands
[4] Gaubius Lab, TNO Metab Hlth Res, NL-2301 CE Leiden, Netherlands
[5] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands
[6] Hannover Med Sch, Inst Clin Pharmacol, D-30625 Hannover, Germany
[7] Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands
关键词
Atherosclerosis; Lipids; Oxidative stress; Inflammation; Resveratrol; Statin; LOW-DENSITY-LIPOPROTEIN; TRANS-RESVERATROL; HUMAN MACROPHAGES; OXIDATIVE STRESS; DEFICIENT MICE; RED WINE; EXPRESSION; INFLAMMATION; COMBINATION; ATTENUATION;
D O I
10.1016/j.jnutbio.2012.11.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Resveratrol is a major constituent of traditional Asian medicinal herbs and red wine and is suggested to be a potential antiatherosclerotic drug due to its proposed hypolipidemic, anti-inflammatory and antioxidative properties. The aim of this study was to evaluate whether resveratrol protects against atherosclerosis development in APOE*3-Leiden.CETP (E3L.CETP) mice and adds to the antiatherogenic effect of mild statin treatment, currently the most widely used antiatherogenic therapy. E3L.CETP mice were fed a cholesterol-rich diet without (control) or with resveratrol (0.01% w/w), atorvastatin (0.0027% w/w) or both for 14 weeks. During the study plasma lipid, inflammatory and oxidative stress parameters were determined. Resveratrol reduced atherosclerotic lesion area (-52%) in the aortic root, comparable to atorvastatin (-40%) and the combination of both drugs (-47%). The collagen/macrophage ratio in the atherosclerotic lesion, a marker of plaque stability, was increased by resveratrol (+108%), atorvastatin (+124%) and the combination (+154%). Resveratrol decreased plasma cholesterol levels (-19%) comparable to atorvastatin (-19%) and the combination (-22%), which was completely confined to (very)low-density lipoprotein cholesterol levels in all groups. Post hoc analyses showed that the antiatherogenic effect of atorvastatin could be explained by cholesterol lowering, while the antiatherosclerotic effect of resveratrol could be attributed to factors additional to cholesterol lowering. Markers of inflammation and oxidative stress were not different, but resveratrol improved macrophage function. We conclude that resveratrol potently reduces atherosclerosis development and induces a more stable lesion phenotype in E3L.CETP mice. However, under the experimental conditions tested, resveratrol does not add to the antiatherogenic effect of atorvastatin. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:1423 / 1430
页数:8
相关论文
共 37 条
[1]
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[2]
Resveratrol improves health and survival of mice on a high-calorie diet [J].
Baur, Joseph A. ;
Pearson, Kevin J. ;
Price, Nathan L. ;
Jamieson, Hamish A. ;
Lerin, Carles ;
Kalra, Avash ;
Prabhu, Vinayakumar V. ;
Allard, Joanne S. ;
Lopez-Lluch, Guillermo ;
Lewis, Kaitlyn ;
Pistell, Paul J. ;
Poosala, Suresh ;
Becker, Kevin G. ;
Boss, Olivier ;
Gwinn, Dana ;
Wang, Mingyi ;
Ramaswamy, Sharan ;
Fishbein, Kenneth W. ;
Spencer, Richard G. ;
Lakatta, Edward G. ;
Le Couteur, David ;
Shaw, Reuben J. ;
Navas, Placido ;
Puigserver, Pere ;
Ingram, Donald K. ;
de Cabo, Rafael ;
Sinclair, David A. .
NATURE, 2006, 444 (7117) :337-342
[3]
Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N- and C-terminal helix [J].
Berbee, Jimmy F. P. ;
Coomans, Claudia P. ;
Westerterp, Marit ;
Romijn, Johannes A. ;
Havekes, Louis M. ;
Rensen, Patrick C. N. .
JOURNAL OF LIPID RESEARCH, 2010, 51 (07) :1943-1952
[4]
A new insight into resveratrol as an atheroprotective compound: Inhibition of lipid peroxidation and enhancement of cholesterol efflux [J].
Berrougui, Hicham ;
Grenier, Guillaume ;
Loued, Soumaya ;
Drouin, Genevieve ;
Khalil, Abdelouahed .
ATHEROSCLEROSIS, 2009, 207 (02) :420-427
[5]
Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters [J].
Cho, Il Jin ;
Ahn, Ji Yun ;
Kim, Suna ;
Choi, Myung Sook ;
Ha, Tae Youl .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 367 (01) :190-194
[6]
Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations [J].
Csiszar, Anna ;
Labinskyy, Nazar ;
Podlutsky, Andrej ;
Kaminski, Pawel M. ;
Wolin, Michael S. ;
Zhang, Cuihua ;
Mukhopadhyay, Partha ;
Pacher, Pal ;
Hu, Furong ;
de Cabo, Rafael ;
Ballabh, Praveen ;
Ungvari, Zoltan .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2008, 294 (06) :H2721-H2735
[7]
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin [J].
de Haan, Willeke ;
de Vries-van der Weij, Jitske ;
van der Hoorn, Jose W. A. ;
Gautier, Thomas ;
van der Hoogt, Caroline C. ;
Westerterp, Marit ;
Romijn, Johannes A. ;
Jukema, J. Wouter ;
Havekes, Louis M. ;
Princen, Hans M. G. ;
Rensen, Patrick C. N. .
CIRCULATION, 2008, 117 (19) :2515-2522
[8]
Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice [J].
Delsing, DJM ;
Jukema, JW ;
van de Wiel, MA ;
Emeis, JJ ;
van der Laarse, A ;
Havekes, LM ;
Princen, HMG .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 42 (01) :63-70
[9]
Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice [J].
den Boer, Marion A. M. ;
Westerterp, Marit ;
de Vries-van der Weij, Jitske ;
Wang, Yanan ;
Hu, Lihui ;
Santo, Sonia M. S. Espirito ;
Kooistra, Teake ;
Reiss, Peter ;
Romijn, Johannes A. ;
Havekes, Louis M. ;
Rensen, Patrick C. N. .
ATHEROSCLEROSIS, 2010, 210 (02) :381-387
[10]
Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice [J].
Do, Gyeong-Min ;
Kwon, Eun-Young ;
Kim, Hye-Jin ;
Jeon, Seon-Min ;
Ha, Tae-Youl ;
Park, Taesun ;
Choi, Myung-Sook .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 374 (01) :55-59